Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Scilex Holding Co's Debt-to-EBITDA or its related term are showing as below:
SCLX'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -4.52 Med: -0.87 Max: -0.14
Current: -0.27
During the past 7 years, the highest Debt-to-EBITDA Ratio of Scilex Holding Co was -0.14. The lowest was -4.52. And the median was -0.87.
SCLX's Debt-to-EBITDA is ranked worse than 100% of 681
companies
in the Drug Manufacturers industry
Industry Median: 1.63
vs SCLX: -0.27
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Scilex Holding Co Debt-to-EBITDA Related Terms
Scilex Holding Co Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Scilex Holding Co's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SCLX vs MIRA, NSRX, MDCX: Debt-to-EBITDA Comparison
For the Drug Manufacturers - General subindustry, Scilex Holding Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scilex Holding Co Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Scilex Holding Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Scilex Holding Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Scilex Holding Co (SCLX) has a Debt-to-EBITDA of -0.84 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Scilex Holding Co. According to the industry distribution chart, Scilex Holding Co ranks #999999 out of 681 companies in the Drug Manufacturers industry.
Is Scilex Holding Co's Debt-to-EBITDA too high?
Scilex Holding Co's current Debt-to-EBITDA is -0.84. Based on the distribution chart, Scilex Holding Co ranks #999999 out of 681 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Scilex Holding Co has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Scilex Holding Co's Debt-to-EBITDA compare to MIRA and NSRX?
According to the Drug Manufacturers industry distribution chart, Scilex Holding Co ranks #999999 out of 681 companies for Debt-to-EBITDA. This places Scilex Holding Co in the lower half of its industry. The industry median Debt-to-EBITDA is 1.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.63, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Scilex Holding Co. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scilex Holding Co's current Debt-to-EBITDA is -0.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scilex Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Scilex Holding Co (SCLX) is currently considered Modestly Overvalued. The stock's GF Value™ is $5.83, compared to a current price of $6.80 — trading 16.6% above its estimated fair value. The current Debt-to-EBITDA is -0.84. Scilex Holding Co's overall GF Score™ is 56/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Scilex Holding Co (SCLX), the current Debt-to-EBITDA is -0.84 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scilex Holding Co (SCLX) Overvalued in 2026?
Based on GuruFocus' analysis, Scilex Holding Co stock appears to be overvalued.
The current stock price of $6.80 is trading 16.6% above its estimated GF Value™ of $5.83.
GuruFocus considers Scilex Holding Co to be Modestly Overvalued.
Key valuation signals for SCLX:
Debt-to-EBITDA: -0.84
GF Value™: $5.83 vs. price of $6.80 (16.6% above fair value)
No single metric tells the full story. See the SCLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
56GF Score
Get the complete analysis for SCLX
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SCLX has been successfully added to your 
